Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance

Davita IncTrade
iShares Self-Driving EV and TechTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs iShares Self-Driving EV and Tech — how do they compare? Davita Inc trades at $177.71 (market cap $11.38B), while iShares Self-Driving EV and Tech trades at $37.53. The key difference: Davita Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.

DVAIDRV
Market Cap
$11.38B
Sector
HealthSector/Thematic
52-Week High
$240.96$45.48
52-Week Low
$103.87$34.49
Enterprise Value
$24.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.

The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.

iShares Self-Driving EV and Tech

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About iShares Self-Driving EV and Tech

IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.

Read more on IDRV